References in periodicals archive ?
Carotid body tumors grow slowly and remain asymptomatic until they reach up to a certain size.
A carotid body tumor usually presents headache or neck pain in 35%, dizziness in 8%, hoarseness in 8% and dysphagia in 8% of patients.
Cibiem is a medical device company leveraging its proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation[TM] (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure.
Carotid body tumor (CBT), first described by von Luschka, 1862 is a rare lesion of the neuroendocrine system.
MRI with magnetic resonance angiography demonstrated the characteristic imaging findings of a carotid body tumour.
The observation made in the present study suggests the involvement of afferent limb of parasympathetic reflex arc which consists of carotid body chemoreceptors, tenth cranial nerve and cardiovascular receptors in medulla.
Patients with a carotid body paraganglioma have the best outcome, whereas those with skull base tumors have a less favorable prognosis because of the increased difficulty in achieving total resection.
INTRODUCTION: Carotid body tumors (CBT) are distinctly uncommon hypervascular neck tumors.
Magnetic resonance imaging of the head and neck demonstrated multiple skull base lesions consistent with bilateral carotid body tumors, a left glomus jugulare, and a right glomus vagale.
In the poststyloid space, they are associated with the carotid body, the jugular bulb, or the vagus nerve.